Global /United States /Healthcare /Diagnostics & Research /TWST
chevron_leftBack

Twist Bioscience Corp.

TWST
NASDAQ: TWST Delayed
37.62USD 1.8%
As of 24 April 2025, Twist Bioscience Corp. has a market cap of $2.24B USD, ranking #4965 globally and #1383 in the United States. It ranks #447 in the Healthcare sector, and #35 in the Diagnostics & Research industry.
Global Rank
4965
Country Rank
1383
Sector Rank
447
Industry Rank
35
Key Stats
Market Cap
$2.24BUSD
Enterprise Value
$2.06BUSD
Revenue (TTM)
$330.19MUSD
EBITDA (TTM)
-$136.53MUSD
Net Income (TTM)
-$197.31MUSD
EBITDA Margin
-41%
Profit Margin
-60%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Emily Leproust open_in_new
Employees
923
Founded
2013
IPO
31 Oct 2018
Website
twistbioscience.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.8% -2.2% -12% -28% -14% 28%
Upcoming Earnings
Earnings Date
Mon, May 5
Earnings Time
sunny Before Open
EPS Estimate
-$0.5700
Revenue Estimate
$92.0M 22% yoy

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
TWST
Twist Bioscience Corp
ISIN: US90184D1000
Shares Out.:
59.651M1 Shares Float: 56.372M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
37.62 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Twist Bioscience Corp.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Similar Companies

Industry: Diagnostics & Research (United States)
Name
Market Cap diff.
Thermo Fisher Scientific Inc.
TMO
$162.94B
7K%
Danaher Corp.
DHR
$140.49B
6K%
IDEXX Laboratories, Inc.
IDXX
$34.57B
1K%
Agilent Technologies, Inc.
A
$29.94B
1K%
IQVIA Holdings Inc.
IQV
$25.93B
1K%
Industry: Diagnostics & Research (Global)
Name
Market Cap diff.
Lonza Group AG
LONN
$48.07B
39.7B CHF
2K%
WuXi AppTec Co., Ltd.
603259
$22.16B
161.5B CNY
888%
bioMérieux S.A.
BIM
$15.23B
13.39B EUR
579%
ICON Public Limited Co.
ICLR
$11.56B
415%
Eurofins Scientific SE
ERF
$11.46B
10.07B EUR
411%